Tariffs on imported generic drugs of up to 200% from 2029 could reshape where and how the medicines in US pharmacies are made, and that has real implications for US-based generic drug stocks. With 90% of US prescriptions filled by generics and about 70% of those sourced from overseas, investors are right to pay attention as policy pressure builds for more domestic manufacturing. This article looks at how that policy shock could affect US-based generic manufacturers and highlights three stocks that might be positioned to benefit from their exposure to this tariff driven news.

Fennec Pharmaceuticals (FENC)

Overview: Fennec Pharmaceuticals is a commercial stage biopharma company focused on PEDMARK, a sodium thiosulfate formulation used to help prevent cisplatin related hearing loss in pediatric cancer patients, sold through a targeted network of pediatric oncology specialists and medical science liaisons in the US.

Operations: Fennec Pharmaceuticals generates about US$51.0 million in revenue from the production and commercialization of PEDMARK in the United States.

Market Cap: US$343.9 million

Investors looking at US based drug makers that could sit on the right side of potential tariffs may find Fennec Pharmaceuticals interesting, as its US manufactured, FDA approved PEDMARK already fits the kind of domestic supply that policymakers are trying to encourage and management has stated that the proposed tariffs are not expected to affect its margins. At the same time, the company is still built around a single product, carries funding risk and has only recently moved into modest profitability, so execution on further adoption, label expansion and international partnerships matters a lot. The combination of tariff insulation, supportive clinical data and a still maturing financial profile leaves more to unpack for anyone weighing up risk and reward here.

Fennec Pharmaceuticals is already insulated from proposed tariffs, but the real story lies in how its single product risk and maturing profitability compare with its potential rewards. The 5 key rewards and 2 important warning signs might show why the headline story is only half the picture.

ANI Pharmaceuticals (ANIP)

Overview: ANI Pharmaceuticals is a US based biopharma company that develops, manufactures, and sells a mix of generic and branded drugs, including injectables, softgel capsules, Cortrophin Gel, ILUVIEN and YUTIQ, to wholesalers, pharmacies, hospitals, and healthcare providers.

Operations: ANI Pharmaceuticals generates about US$405.6 million from Generics and Other products and US$518.1 million from its Rare Disease and Brands segment.

Market Cap: US$1.6b

Investors watching tariff sensitive generic drug stocks may see ANI Pharmaceuticals as a potential beneficiary of the proposed 100% to 200% tariffs because management reports that over 90% of its revenue already comes from US manufactured finished goods and less than 5% relies directly on China, with spare capacity in its US plants to serve any reshoring driven demand shift. At the same time, the story involves some tension, given its reliance on high value products like Cortrophin Gel, a balance sheet funded entirely by higher risk borrowing, and recent product recalls and regulatory actions. How those strengths and pressure points interact under the new tariff backdrop is a central point for investor analysis.

Tariff tailwinds, high value drugs and a fully debt funded balance sheet make ANI Pharmaceuticals tougher to read than it looks at first glance, and the 4 key rewards and 3 important warning signs could clarify what is driving the real risk reward trade off ahead

Viatris (VTRS)

Overview: Viatris is a global healthcare company that sells a wide range of branded drugs, generics, complex generics, and biosimilars across major therapeutic areas such as cardiovascular disease, diabetes, oncology, respiratory conditions, and more, supported by patient services like diagnostic clinics and digital tools.

Operations: Viatris generates about US$8.7b in revenue from Developed Markets, US$2.5b from Greater China, US$2.2b from Emerging Markets, and US$1.2b from its JANZ segment.

Market Cap: US$19.8b

Viatris stands out in this generic drug list because it combines a broad global footprint with sizeable US manufacturing, which could matter a lot if tariffs on imported generics reach 200% and reward companies with domestic production. The company already sources more than half of its US revenue from US plants, is working on higher margin products like complex generics and biosimilars, and has recently reported a move back into profitability with reaffirmed 2026 guidance. At the same time, Viatris still relies heavily on mature generics, carries meaningful debt, and faces ongoing pricing and regulatory pressure. How that mix of tariff exposure, product upgrades and balance sheet risk plays out is where the real opportunity and caution sit for investors.

Viatris looks like a reshoring winner in waiting, with U.S. manufacturing and complex generics potentially masking a very different risk reward story, and the 3 key rewards and 1 important warning sign could reveal what the headline tariff angle is missing

The three stocks covered here are just a starting point, and the full US-Based Generic Drug Manufacturers screener on Simply Wall St has identified 7 more companies with equally compelling narratives that could sit in the same tariff focused sweet spot as these US operators. It is worth scanning the complete US-Based Generic Drug Manufacturers screener to round out your watchlist.

Use Simply Wall St to analyze and filter those companies for the specific catalysts and narratives covered here, so you can identify higher conviction generic drug opportunities that fit your own risk, balance sheet and growth preferences.

Take Control of Your Investment Journey

If ANI Pharmaceuticals or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About Alternative Stock Paths?

Fresh stock ideas do not stay under the radar for long, and once momentum builds, ideal entry points can be gone before the crowd catches on. Consider acting promptly and thoughtfully when you identify opportunities that fit your strategy.

• Spot companies with share prices lagging their fundamentals and use the 50 high quality undervalued stocks to see which opportunities might align with your criteria.
• Back test your income goals against the 9 dividend fortresses and see which high yield payers could help support your cash flow objectives while others focus on different approaches.
• Monitor sector shifts by scanning the 81 resilient stocks with low risk scores where resilient businesses may be more aligned with investors who prioritize steadier ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.